LitAlert ~~ GeneLit.com

    • Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?
    • Rao A, Moka N, Hamstra DA, Ryan CJ.
    • Cancers (Basel). 2022 Feb 4;14(3):801. doi: 10.3390/cancers14030801.
    • Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    • Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, Yang K, Wu HC, Chao TY, Chang YC, Lin PC, Kuo WH, Kuo WL, Lin CH, Chen HM, Yeh DC, Liu LC, Liu CY, Wang MY, Lo C, Lu YS, Huang CS.
    • Breast Cancer Res Treat. 2022 Feb 3. doi: 10.1007/s10549-021-06446-7. Epub ahead of print.
    • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.
    • Petrucelli N, Daly MB, Pal T.
    • 1998 Sep 4 [updated 2022 Feb 3]. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors.
    • Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
    • Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, Chae YS, Lee SJ, Lee IH, Lee NY.
    • Sci Rep. 2022 Feb 3;12(1):1842. doi: 10.1038/s41598-022-05931-3.
    • Cell-type-specific epigenomic variations associated with BRCA1 mutation in pre-cancer human breast tissues.
    • Hsieh YP, Naler LB, Ma S, Lu C.
    • NAR Genom Bioinform. 2022 Feb 2;4(1):lqac006. doi: 10.1093/nargab/lqac006.